Wed, May 14, 10:14 AM (41 days ago)
**Nexien BioPharma, Inc. (NEXIEN) Q1 2025 Financial Summary** **Financial Health and Performance:** - **Revenue:** No revenue reported for Q1 2025. - **Net Loss:** $30,092,000, a decrease of $23,071,000 from Q1 2024. - **Cash Position:** $8,285,000, up from $4,183,000 in Q1 2024. - **Working Capital Deficit:** $450,516,000, increased from $361,249,000 in Q1 2024. - **Total Liabilities:** $458,801,000, up from $365,432,000 in Q1 2024. - **Total Assets:** $8,285,000, up from $4,183,000 in Q1 2024. **Profit Margins:** - **Operating Expenses:** $14,300,000, slightly down from $15,947,000 in Q1 2024. - **Interest Expense:** $11,429,000, up from $10,238,000 in Q1 2024. - **Amortization of Discount on Convertible Notes:** $4,363,000, down from $26,978,000 in Q1 2024. **Cash Flow:** - **Operating Cash Flow:** Negative $50,898,000, slightly improved from negative $53,480,000 in Q1 2024. - **Financing Cash Flow:** Positive $55,000,000, up from $28,400,000 in Q1 2024. **Earnings Changes:** - **Loss per Share:** $0.000, improved from $0.001 in Q1 2024. - **Weighted Average Shares Outstanding:** 70,772,196, up from 66,384,284 in Q1 2024. **Quarterly Performance Discussion:** - **Operational Costs:** Primarily related to maintaining public company status. - **Financing Activities:** Included advances from the CEO and convertible notes from Quick Capital. - **Going Concern:** Significant doubt about the company's ability to continue as a going concern due to lack of revenue and substantial capital requirements. **Trends and Uncertainties:** - **Capital Needs:** Requires significant additional capital to fund operations and drug development. - **Market Risks:** No quantitative or qualitative disclosures about market risk provided. - **Future Operations:** Seeking merger or business combination opportunities due to financial constraints. **Future Impact:** - **Capital Raising:** Needs to raise at least $40,000,000 to maintain existence as a public company. - **Operational Continuity:** Dependent on securing additional funding or strategic arrangements. - **Regulatory Approval:** Long-term success hinges on obtaining regulatory approval for drug candidates.